SAR-BRI Sequence Enhances Recombinant Protein Expression Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current S/MAR sequences used in expression vectors are often large and impractical for incorporation, and not all sequences provide beneficial effects for enhancing protein expression and stability in mammalian cells, necessitating the identification of shorter, functional S/MAR sequences for improved recombinant protein production.
Innovation Solution
Incorporation of the SAR-BRI sequence, a 70-bp S/MAR element, into expression vectors such as pTT54-EPO and pTT54-TZMHc, which enhances protein expression levels and stability by facilitating the generation of stable cell pools and clones without the need for continuous selection pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large S/MAR sequences (1.5 to 4 kb) are incorporated into expression vectors, then expression enhancement and stability are achieved, but the vector size becomes impractical for incorporation and use
Solution Approach 1:
The patent extracts only the essential functional portion of the S/MAR sequence (70 bp from interferon alpha-2) that is sufficient to provide chromatin scaffolding and expression stability, removing the non-essential bulk of the original larger sequences (1.5 to 4 kb). This extracted minimal sequence maintains the key function while dramatically reducing size for practical vector incorporation.
Solution Approach 2:
The patent identifies and utilizes a specific local region within the S/MAR sequence (nucleotides 1000-1750 of interferon alpha-2) that contains the critical functional elements for chromatin attachment and expression enhancement. This local quality approach focuses on the most effective 70 bp segment rather than using entire large S/MAR sequences.
2Productivity
If S/MAR sequences are incorporated to enhance expression levels, then productivity increases, but not all sequences provide beneficial effects and some may be ineffective
Solution Approach 1:
The patent changes the key parameter of sequence length to 70 bp based on empirical optimization, identifying that this specific length provides the optimal balance between functionality and efficiency. This parameter change ensures reliable expression enhancement while avoiding the variability associated with using different large S/MAR sequences of unknown effectiveness.
3Stability of the object's composition
If continuous selection pressure is applied to maintain stable cell lines, then expression stability is maintained, but the process complexity and cost increase
Solution Approach 1:
The S/MAR sequence enables the cell line to self-maintain stable expression without requiring continuous external selection pressure. The chromatin scaffolding function of the S/MAR element inherently stabilizes the transgene expression, allowing the system to maintain stability autonomously rather than requiring complex continuous selection processes.
Data Source
AI summary
A short human genomic nucleotide sequence from the SAR3 region of the human interferon a2 gene permits enhances expression stability in the absence of drug selection and permits generation of stable clones or stable pools of cells for producing recombinant proteins. Although stable clones may be generated, the ability to generate stable pools reduces the burden of generating stable clones.